Latest Intelligence on Vaccines in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Abbott's flu vaccine business may represent a good deal for acquisitive drug makers

According to media reports, pharmaceutical company Abbott Laboratories is looking to auction off its influenza vaccine business in a deal that could be worth up to $600m. Abbott's established link to the Russian flu market and its advanced cell-based technology make the business an attractive prospect for would-be buyers, which may include the likes of GlaxoSmithKline and MedImmune.

Published By Datamonitor
29 Jun 2010
CommentWire
CommentWire

Antigenics: Oncophage EU marketing application likely to fail

Antigenics is seeking EU approval for Oncophage in early-stage renal cell carcinoma. Despite there currently being no approved drugs for the post-surgical treatment of adjuvant kidney cancer in the EU or US, Oncophage's application is expected to fail. Antigenics will have to provide more robust evidence of Oncophage's efficacy if it wishes to gain approval in the lucrative US and EU markets.

Published By Datamonitor
22 Oct 2009
Expert View
Expert View

BiondVax: new Phase II data heat up the race for the first universal influenza vaccine

New data presented at the World Vaccines Congress demonstrate that BiondVax's developmental influenza vaccine can also act as a booster to existing seasonal influenza vaccines in elderly patients. A vaccine with increased efficacy in the elderly is one of the largest unmet needs in influenza prevention, although the need for patients to take multiple vaccinations may hinder its success.

Published By Datamonitor
13 Apr 2012
CommentWire
CommentWire

Bird flu: current measures may not be enough

Faced by growing fears of a flu epidemic on the scale of those seen in the early twentieth century, the UK Department of Health has confirmed it is drawing up plans to deal with a possible bird flu crisis. Though vaccine manufacturers Chiron and Aventis-Pasteur have announced imminent initiation of human testing for bird flu vaccines, wider issues over prophylactic provision remain.

Published By Datamonitor
15 Dec 2004
CommentWire
CommentWire

Chiron: rising from the ashes

After a troubling few years, Chiron has posted strong fourth-quarter 2005 sales and profits, driven by the recommencement of Fluvirin sales. These impressive results have boosted the company's share price and gone some way towards restoring confidence, which took a big knock in October 2004 when UK authorities suspended the company's flu vaccine license.

Published By Datamonitor
03 Feb 2006
CommentWire
CommentWire

Crucell: failed vaccine disappoints

Crucell has halted development of Aerugen, its late-stage vaccine candidate for the prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients, following disappointing phase III trial results. Although this is something of a setback for vaccine development within the field of cystic fibrosis, other efforts focusing on ion channel therapy still provide a glimmer of hope.

Published By Datamonitor
19 Jul 2006
Expert View
Expert View

FIGO 2009: focus moves towards cervical cancer and overactive bladder

Among the key developments at this year's International Federation of Gynecology and Obstetrics meeting, pharmaceutical companies aimed to improve awareness of overactive bladder. Elsewhere, the reduction of mortality due to cervical cancer emerged as a key theme among delegates, with discussions of vaccine strategies not only in the developed world but also in developing countries.

Published By Datamonitor
13 Oct 2009
CommentWire
CommentWire

GlaxoSmithKline: dose-sparing H5N1 vaccine application filed in Europe

With its application for an H5N1 vaccine being accepted for review in Europe, GlaxoSmithKline has become the first company to seek approval for an adjuvant-enhanced H5N1 vaccine that permits many doses to be produced for mass vaccination. This puts GSK in a good position to be contracted by governments for vaccine stockpiling, although other firms developing similar vaccines are not far behind.

Published By Datamonitor
31 Jan 2007
CommentWire
CommentWire

GlaxoSmithKline: H1N1 hype unfounded as UK caps vaccine order

Following poor uptake of the vaccine in several European markets, the UK Department of Health has opted to limit its H1N1 contract with GlaxoSmithKline to 34.8 million doses. Despite the media hype surrounding the influenza outbreak, the mild course of the pandemic and negative public opinion of the vaccine means that its commercial impact will be significantly reduced.

Published By Datamonitor
08 Apr 2010
CommentWire
CommentWire

GSK: tying the knot with partner Corixa

The acquisition of Seattle-based Corixa is a timely move by GSK [GSK.L], as the deal gives it ownership of key agents in its own vaccine portfolio. Most promisingly, GSK gains control of MPL - a key ingredient in the possible blockbuster Cervarix. The purchase also underlines the role the biotech sector has to play in driving R&D innovation in the wider pharma industry.

Published By Datamonitor
04 May 2005

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.